Targeted sleep care during tobacco or cannabis quitting
Impact of an Intervention Targeting Sleep Disorders During Tobacco or Cannabis Cessation Therapy: a Randomised Pilot Study
This pilot will test whether systematically screening for and treating sleep problems during quitting programs helps adults stopping tobacco or cannabis stay abstinent longer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier St Anne Academic / other |
| Locations | 1 site (Paris, Île-de-France Region) |
| Trial ID | NCT07202351 on ClinicalTrials.gov |
What this trial studies
In a randomized pilot at two addiction care centres in Paris, adults seeking help to quit tobacco or cannabis will be assigned to usual multidisciplinary care or to the same care plus systematic sleep disorder screening. Patients in the intervention arm who screen positive will be referred to the Chronos centre for targeted sleep management. The trial will follow participants over six months with scheduled clinic visits to track sleep symptoms and substance abstinence. The primary aim is to see if identifying and managing sleep disorders reduces relapse during cessation treatment.
Who should consider this trial
Good fit: Adults (18+) seeking tobacco or cannabis cessation at the participating Paris addiction centres who are covered by French health insurance and willing to accept additional sleep screening and referral are ideal candidates.
Not a fit: People already receiving treatment for sleep disorders, hospitalized during cessation, diagnosed with psychotic disorders, participating in another study, or who decline the additional intervention are unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, this approach could lower relapse rates and improve sleep quality for people trying to quit tobacco or cannabis.
How similar studies have performed: Previous research has linked sleep problems to relapse and some sleep-focused interventions have shown promise, but systematic targeted management during cessation remains relatively untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients over 18 years old * presenting at the participating addiction treatment centres for a smoking or cabannis use cessation therapy * who agree to participate to the study * affiliated to the French health insurance system Exclusion Criteria: * Patients hospitalised during the cessation therapy * Patients undergoing sleep disorders treatment * Patients participating to another study * Patients with psychotic disorders (according the DSM-5 classification) * Patients who do not want the additionnal intervention and care if randomised in the intervention group
Where this trial is running
Paris, Île-de-France Region
- GHU Paris Psychiatrie et Neurosciences — Paris, Île-de-France Region, France (Recruiting)
Study contacts
- Study coordinator: Anne PEROZZIELLO
- Email: a.perozziello@ghu-paris.fr
- Phone: 01.80.52.67.54
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.